亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

岳陽市嘉誠生物科技有限公司銷售部  

高效氯氟氰菊酯,匹可硫酸鈉,溴蟲睛,3,4,5一三甲氧基肉桂酸,2,4一二羥基苯甲酸,三乙脂,烯丙基硫脲

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:熊先生
  • 電話:0730-8705981
  • 郵件:gcns08@ycgmp.com
  • 傳真:0730-8705981
  • QQ:2355779402
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產(chǎn)品 > 腺苷原藥廠家
腺苷原藥廠家
單價 面議對比
詢價 暫無
發(fā)貨 湖南岳陽市付款后3天內(nèi)
品牌 南箭
過期 長期有效
更新 2019-06-27 09:08
 
詳細信息
 腺苷原藥廠家
中文同義詞:9-beta-D-呋喃核糖基腺嘌呤;腺甙;腺嘌呤核苷;腺苷;腺嘌呤核苷(腺苷);D-腺嘌呤核苷;腺呤配糖;腺尿環(huán)核苷
英文名稱:Adenosine
英文同義詞:D-ADENOSINE;AR;(2R,3R,4S,5R)-2-(6-AMINO-PURIN-9-YL)-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-3,4-DIOL;9-BETA-D-RIBOFURANOSYLADENINE;ADENINENUCLEOSIDE;ADENINE RIBOSIDE;ADENOSINE;ADENINE-9-BETA-D-RIBOFURANOSIDE
CAS號: 58-61-7
分子式: C10H13N5O4
分子量: 267.24
 
 腺苷原藥廠家

©2025 岳陽市嘉誠生物科技有限公司銷售部 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:12074  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |